BioWorld MedTech

Sep. 13, 2016

Alere, Abbott agree to mediation, not much else in contested merger nuptials

A court battle between Alere Inc. and its potential acquirer Abbott Labs could be inching towards a resolution. The two sides agreed last week to work with a mediator to resolve the dispute, which has landed in the Delaware Chancery Court. Read More

Sanofi, Verily Life Sciences invest $500M for their Onduo diabetes-focused collaboration

BSX's Craig Thompson shares perspectives on the interventional cardiology market

Mylan has invested $1B to raise awareness of need for Epipen

Attorney says FDA faces losing court battles over tissue therapy regulation

Other news to note

Appointments and advancements

Financings

Product briefs

MDD's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...